A Phase 2 Open-Label, Single-Arm Trial of the Efficacy of Topical Remetinostat on Basal Cell Carcinoma in Patients
Phase of Trial: Phase II
Latest Information Update: 02 Aug 2018
At a glance
- Drugs Remetinostat (Primary)
- Indications Basal cell cancer
- Focus Therapeutic Use
- 02 Aug 2018 According to a Medivir AB media release, first patient has been enrolled in this study.
- 10 Jul 2018 Status changed from not yet recruiting to recruiting.
- 18 Jan 2018 Planned End Date changed from 30 Jun 2019 to 31 Dec 2019.